Olivera J. Finn is a Yugoslav-American immunologist who is a distinguished professor and former chair of the Department of Immunology at the University of Pittsburgh and former director of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute. Gerold Schuler is the editor of The Renaissance of Cancer Immunotherapy: The 7th International Cancer Vaccine Symposium, Volume 1284, published by Wiley.

• Introduction to The Renaissance of Cancer Immunotherapy vOlivera J. Finn and Gerold SchulerCancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy 1Matthews D. Vesely and Robert D. SchreiberCell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells 6Maurizio ZanettiImmunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance 12Bridget Keenan and Elizabeth M. JaffeeIntegration of epidemiology, immunobiology, and translational research for brain tumors 17Hideho Okada, Michael E. Scheurer, Saumendra N. Sarkar, and Melissa L. BondyHuman dendritic cells subsets as targets and vectors for therapy 24Eynav Klechevsky and Jacques BanchereauDendritic cell immunotherapy 31Rachel Lubong Sabado and Nina BhardwajMolecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance 46Dylan J. Johnson and Pamela S. OhashiPreventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas 52Pamela L. Beatty and Olivera J. FinnImmunological control of cell cycle aberrations for avoidance of oncogenesis: the case of tetraploidy 57Laura Senovilla, Lorenzo Galluzzi, Maria Castedo, and Guido KroemerOngoing adaptive immune responses in the microenvironment of melanoma metastases 62Nicolas van Baren and Pierre G. CoulieMain features of human T helper 17 cells 66Francesco Annunziato, Lorenzo Cosmi, Francesco Liotta, Enrico Maggi, and Sergio RomagnaniIn silico modeling of cancel cell dissemination and metastasis 71Lu-En Wai, Vipin Narang, Alexandre Gouaillard, Lai Guan Ng, and Jean-Pierre AbastadoCommon pathways to tumor rejection 75Ena Wang, Davide Bedognetti, Sara Tomei, and Francesco M. MarincolaCancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy 80Yutaka Kawakami, Tomonori Yaguchi, Hidetoshi Sumimoto, Chie Kudo-Saito, Nobuo Tsukamoto. Tomoko Iwata-Kajihara, Shoko Nakamura, Hiroshi Nishio, Ryosuke Satomi, Asuka Kobayashi, Mayuri Tanaka, Jeong Hoon Park, Hajime Kamijuku, Takahiro Tsujikawa, and Naoshi Kawamura

Olivera J. Finn is a Yugoslav-American immunologist who is a distinguished professor and former chair of the Department of Immunology at the University of Pittsburgh and former director of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute. Gerold Schuler is the editor of The Renaissance of Cancer Immunotherapy: The 7th International Cancer Vaccine Symposium, Volume 1284, published by Wiley.

• Introduction to The Renaissance of Cancer Immunotherapy vOlivera J. Finn and Gerold SchulerCancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy 1Matthews D. Vesely and Robert D. SchreiberCell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells 6Maurizio ZanettiImmunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance 12Bridget Keenan and Elizabeth M. JaffeeIntegration of epidemiology, immunobiology, and translational research for brain tumors 17Hideho Okada, Michael E. Scheurer, Saumendra N. Sarkar, and Melissa L. BondyHuman dendritic cells subsets as targets and vectors for therapy 24Eynav Klechevsky and Jacques BanchereauDendritic cell immunotherapy 31Rachel Lubong Sabado and Nina BhardwajMolecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance 46Dylan J. Johnson and Pamela S. OhashiPreventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas 52Pamela L. Beatty and Olivera J. FinnImmunological control of cell cycle aberrations for avoidance of oncogenesis: the case of tetraploidy 57Laura Senovilla, Lorenzo Galluzzi, Maria Castedo, and Guido KroemerOngoing adaptive immune responses in the microenvironment of melanoma metastases 62Nicolas van Baren and Pierre G. CoulieMain features of human T helper 17 cells 66Francesco Annunziato, Lorenzo Cosmi, Francesco Liotta, Enrico Maggi, and Sergio RomagnaniIn silico modeling of cancel cell dissemination and metastasis 71Lu-En Wai, Vipin Narang, Alexandre Gouaillard, Lai Guan Ng, and Jean-Pierre AbastadoCommon pathways to tumor rejection 75Ena Wang, Davide Bedognetti, Sara Tomei, and Francesco M. MarincolaCancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy 80Yutaka Kawakami, Tomonori Yaguchi, Hidetoshi Sumimoto, Chie Kudo-Saito, Nobuo Tsukamoto. Tomoko Iwata-Kajihara, Shoko Nakamura, Hiroshi Nishio, Ryosuke Satomi, Asuka Kobayashi, Mayuri Tanaka, Jeong Hoon Park, Hajime Kamijuku, Takahiro Tsujikawa, and Naoshi Kawamura

Olivera J. Finn is a Yugoslav-American immunologist who is a distinguished professor and former chair of the Department of Immunology at the University of Pittsburgh and former director of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute. Gerold Schuler is the editor of The Renaissance of Cancer Immunotherapy: The 7th International Cancer Vaccine Symposium, Volume 1284, published by Wiley.

• Introduction to The Renaissance of Cancer Immunotherapy vOlivera J. Finn and Gerold SchulerCancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy 1Matthews D. Vesely and Robert D. SchreiberCell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells 6Maurizio ZanettiImmunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance 12Bridget Keenan and Elizabeth M. JaffeeIntegration of epidemiology, immunobiology, and translational research for brain tumors 17Hideho Okada, Michael E. Scheurer, Saumendra N. Sarkar, and Melissa L. BondyHuman dendritic cells subsets as targets and vectors for therapy 24Eynav Klechevsky and Jacques BanchereauDendritic cell immunotherapy 31Rachel Lubong Sabado and Nina BhardwajMolecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance 46Dylan J. Johnson and Pamela S. OhashiPreventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas 52Pamela L. Beatty and Olivera J. FinnImmunological control of cell cycle aberrations for avoidance of oncogenesis: the case of tetraploidy 57Laura Senovilla, Lorenzo Galluzzi, Maria Castedo, and Guido KroemerOngoing adaptive immune responses in the microenvironment of melanoma metastases 62Nicolas van Baren and Pierre G. CoulieMain features of human T helper 17 cells 66Francesco Annunziato, Lorenzo Cosmi, Francesco Liotta, Enrico Maggi, and Sergio RomagnaniIn silico modeling of cancel cell dissemination and metastasis 71Lu-En Wai, Vipin Narang, Alexandre Gouaillard, Lai Guan Ng, and Jean-Pierre AbastadoCommon pathways to tumor rejection 75Ena Wang, Davide Bedognetti, Sara Tomei, and Francesco M. MarincolaCancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy 80Yutaka Kawakami, Tomonori Yaguchi, Hidetoshi Sumimoto, Chie Kudo-Saito, Nobuo Tsukamoto. Tomoko Iwata-Kajihara, Shoko Nakamura, Hiroshi Nishio, Ryosuke Satomi, Asuka Kobayashi, Mayuri Tanaka, Jeong Hoon Park, Hajime Kamijuku, Takahiro Tsujikawa, and Naoshi Kawamura